Last reviewed · How we verify
Zagazig
Zagazig is a Small molecule drug developed by Zagazig University. It is currently in Phase 1 development. Also known as: Antibiotic & Analgesic.
Zagazig is a city in Egypt, located in the eastern part of the Nile delta and serving as the capital of the Sharqia governorate. Zagazig University is involved in medical research, including a study on asthma diagnosis at Zagazig University Hospitals.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Zagazig |
|---|---|
| Also known as | Antibiotic & Analgesic |
| Sponsor | Zagazig University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Concept Mapping: as a Tool for Problem Based Learning (NA)
- Assessment of Asthma Mimics Among Newly Diagnosed Bronchial Asthma Patients (NA)
- Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection (PHASE3)
- Misoprostol With or Without Letrozole in Treatment of Missed Miscarriage
- Incidental Finding of Gastrointestinal Stromal Tumors (GISTs) During Laparoscopic Sleeve Gastrectomy, How to Deal? How Much Safety Margin (NA)
- Risk Factors for Potential Drug -Drug Interactions: Study in Surgical Intensive Care Unit -Zagazig University Hospitals.
- Effect of Mebo Dressing Versus Standard Care on Managing Donor and Recipient Sites of Split-thickness Skin Graft (PHASE1)
- Acute-On-Chronic Liver Failure in Zagazig University Hospitals
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zagazig CI brief — competitive landscape report
- Zagazig updates RSS · CI watch RSS
- Zagazig University portfolio CI
Frequently asked questions about Zagazig
What is Zagazig?
Who makes Zagazig?
Is Zagazig also known as anything else?
What development phase is Zagazig in?
Related
- Manufacturer: Zagazig University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Antibiotic & Analgesic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing